Bristol-Myers Squibb (0R1F) Share Forecast & Price Target
0R1F Analyst Ratings
Moderate Buy
9Buy12Hold1Sell
Based on 22 analysts giving stock ratings to Bristol-Myers Squibb in the past 3 months
0R1F Stock 12 Month Forecast
Average Price Target
$66.14â–²(5.44% Upside)Based on 22 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $66.14 with a high forecast of $80.00 and a low forecast of $40.00. The average price target represents a 5.44% change from the last price of $62.73.
Past 12 Months12 Month ForecastDec2025Sep2026
High$80.00
Average$66.14
Low$40.00
Highest Price TargetHighest$80.00Average Price Target$66.14Lowest Price TargetLowest$40.00
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Evan Seigerman | BMO Capital | $61→$60 | hold | -4.35%Downside | Reiterated | 10/30/26 | ||
| Louise Chen | Scotiabank | $60 | hold | -4.35%Downside | Reiterated | 10/30/26 | ||
| Terence Flynn | Morgan Stanley | $41→$40 | sell | -36.23%Downside | Reiterated | 10/30/26 | ||
| Mohit Bansal | Wells Fargo | $65→$60 | hold | -4.35%Downside | Reiterated | 10/30/26 | ||
| Trung Huynh | RBC Capital | $64 | hold | 2.02%Upside | Reiterated | 10/29/26 | ||
| Emily Field | Barclays | $75 | buy | 19.56%Upside | Reiterated | 10/29/26 | ||
| Matt Phipps | William Blair | ― | hold | ― | Reiterated | 10/29/26 | ||
| Jason Gerberry | Bank of America Securities | $66→$67 | buy | 6.81%Upside | Reiterated | 10/29/26 | ||
| Seamus Fernandez | Guggenheim | $75 | buy | 19.56%Upside | Reiterated | 10/29/26 | ||
| Carter Gould | Cantor Fitzgerald | $53 | hold | -15.51%Downside | Reiterated | 10/29/26 | ||
| David Amsellem | Piper Sandler | $78 | buy | 24.34%Upside | Reiterated | 10/27/26 | ||
| Courtney Breen | Bernstein | $61 | hold | -2.76%Downside | Reiterated | 10/25/26 | ||
| Asad Haider | Goldman Sachs | $63 | hold | 0.43%Upside | Assigned | 10/19/26 | ||
| Geoff Meacham | Citi | $70 | hold | 11.59%Upside | Reiterated | 10/13/26 | ||
| Srikripa Devarakonda | Truist Financial | $70 | buy | 11.59%Upside | Reiterated | 10/13/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Evan Seigerman | 10/30/26 | $61→$60 | hold | -4.35%Downside | Reiterated | BMO Capital | ||
| Louise Chen | 10/30/26 | $60 | hold | -4.35%Downside | Reiterated | Scotiabank | ||
| Terence Flynn | 10/30/26 | $41→$40 | sell | -36.23%Downside | Reiterated | Morgan Stanley | ||
| Mohit Bansal | 10/30/26 | $65→$60 | hold | -4.35%Downside | Reiterated | Wells Fargo | ||
| Trung Huynh | 10/29/26 | $64 | hold | 2.02%Upside | Reiterated | RBC Capital | ||
| Emily Field | 10/29/26 | $75 | buy | 19.56%Upside | Reiterated | Barclays | ||
| Matt Phipps | 10/29/26 | ― | hold | ― | Reiterated | William Blair | ||
| Jason Gerberry | 10/29/26 | $66→$67 | buy | 6.81%Upside | Reiterated | Bank of America Securities | ||
| Seamus Fernandez | 10/29/26 | $75 | buy | 19.56%Upside | Reiterated | Guggenheim | ||
| Carter Gould | 10/29/26 | $53 | hold | -15.51%Downside | Reiterated | Cantor Fitzgerald | ||
| David Amsellem | 10/27/26 | $78 | buy | 24.34%Upside | Reiterated | Piper Sandler | ||
| Courtney Breen | 10/25/26 | $61 | hold | -2.76%Downside | Reiterated | Bernstein | ||
| Asad Haider | 10/19/26 | $63 | hold | 0.43%Upside | Assigned | Goldman Sachs | ||
| Geoff Meacham | 10/13/26 | $70 | hold | 11.59%Upside | Reiterated | Citi | ||
| Srikripa Devarakonda | 10/13/26 | $70 | buy | 11.59%Upside | Reiterated | Truist Financial |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Bristol-Myers Squibb
3 Months
Success Rate13/17 ratings generated profit
76%
Average Return
+9.46%
Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +9.46% per trade.
1 Year
Success Rate11/13 ratings generated profit
85%
Average Return
+18.76%
Copying David Amsellem's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +18.76% per trade.
2 Years
Success Rate16/17 ratings generated profit
94%
Average Return
+27.21%
Copying Srikripa Devarakonda's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +27.21% per trade.
0R1F Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 19 | 22 | 21 | 16 | 20 |
| Hold | 27 | 30 | 28 | 33 | 40 |
| Sell | 1 | 2 | 2 | 3 | 5 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 47 | 54 | 51 | 52 | 65 |
In the current month, 0R1F has received 20 Buy Ratings, 40 Hold Ratings, and 5 Sell Ratings. 0R1F average Analyst price target in the past 3 months is 66.14.
0R1F Financial Forecast
High$1.72
Consensus$1.52
Low$1.32
0R1F Earnings Forecast
Next quarter’s earnings estimate for 0R1F is $1.52 with a range of $1.32 to $1.72. The previous quarter’s EPS was $1.35. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$13B
Consensus$12.7B
Low$12.4B
0R1F Sales Forecast
Next quarter’s sales forecast for 0R1F is $12.66B with a range of $12.42B to $13.03B. The previous quarter’s sales results were $13.08B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0R1F Stock Forecast FAQ
What is GB:0R1F’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is $66.14.
What is GB:0R1F’s upside potential, based on the analysts’ average price target?
Bristol-Myers Squibb has 5.44% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Bristol-Myers Squibb a Buy, Sell or Hold?
Bristol-Myers Squibb has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 12 hold ratings and 1 sell ratings.
What is Bristol-Myers Squibb’s share price target?
The average share price target for Bristol-Myers Squibb is $66.14. This is based on 22 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $80.00, and the lowest forecast is $40.00. The average share price target represents a 5.44% increase from the current price of $62.73.
What do analysts say about Bristol-Myers Squibb?
Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Street analysts.
How can I buy shares of Bristol-Myers Squibb?
To buy shares of GB:0R1F, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.